Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys

Molecular Pharmaceutics

Volumn 6, Issue 4, 2009, Pages 1145-1151

  Durand Gasselin, Lucie ^a   Van Rompay, Koen K A ^b   Vela, Jennifer E ^a   Henne, Ilana N ^a   Lee, William A ^a   Rhodes, Gerry R ^a   Rayz, Adrian S ^a  

^a GILEAD SCIENCES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HIV; Nucleotide; Prodrug; Tenofovir

Indexed keywords

NUCLEOTIDE DERIVATIVE; PRODRUG; TENOFOVIR DISOPROXIL;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CELL; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG HALF LIFE; IMMUNE DEFICIENCY; LIPID MEMBRANE; LYMPHOID CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHOSPHORYLATION; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS;

ADENINE; ADMINISTRATION, ORAL; ANIMALS; ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; HALF-LIFE; LYMPHOCYTES; MACACA MULATTA; PHOSPHONIC ACIDS; PHOSPHORYLATION; PRODRUGS; TISSUE DISTRIBUTION;

EID: 68249104931     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900036s     Document Type: Article

References (29)

1. Robbins, B. L.; Srinivas, R. V.; Kim, C.; Bischofberger, N.; Fridland, A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2- phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob. Agents Chemother. 1998, 42, 612-617. (Pubitemid 28114817)
2. Barditch-Crovo, P.; Deeks, S. G.; Collier, A.; Safrin, S.; Coakley, D. F.; Miller, M.; Kearney, B. P.; Coleman, R. L.; Lamy, P. D.; Kahn, J. O.; McGowan, I.; Lietman, P. S. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 2001, 45, 2733-2739.
3. Kearney, B. P.; Flaherty, J. F.; Shah, J. Tenofovir disoproxil fumarate: Clinical pharmacology and pharmacokinetics. Clin. Pharmacokinet. 2004, 43, 595-612. (Pubitemid 38951802)
4. Lee, W. A.; He, G. X.; Eisenberg, E.; Cihlar, T.; Swaminathan, S.; Mulato, A.; Cundy, K. C. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob. Agents Chemother. 2005, 49, 1898-1906.
5. van Gelder, J.; Deferme, S.; Naesens, L.; De Clercq, E.; van den Mooter, G.; Kinget, R.; Augustijns, P. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab. Dispos. 2002, 30, 924-930. (Pubitemid 34815423)
6. Tong, L.; Phan, T. K.; Robinson, K. L.; Babusis, D.; Strab, R.; Bhoopathy, S.; Hidalgo, I. J.; Rhodes, G. R.; Ray, A. S. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob. Agents Chemother. 2007, 51, 3498-3504.
7. National Research Council Guide for the care and use of laboratory animals; National Academy Press: Washington, DC, 1996.
8. Van Rompay, K. K.; Blackwood, E. J.; Landucci, G.; Forthal, D.; Marthas, M. L. Role of CD8+ cells in controlling replication of nonpathogenic Simian Immunodeficiency Virus SIVmac1A11. Virol. J. 2006, 3, 22.
9. Durand-Gasselin, L.; Da Silva, D.; Benech, H.; Pruvost, A.; Grassi, J. Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. Antimicrob. Agents Chemother. 2007, 51, 2105-2111.
10. Benech, H.; Theodoro, F.; Herbet, A.; Page, N.; Schlemmer, D.; Pruvost, A.; Grassi, J.; Deverre, J. R. Peripheral blood mononuclear cell counting using a DNA-detection-based method. Anal. Biochem. 2004, 330, 172-174. (Pubitemid 38746990)
11. Pruvost, A.; Negredo, E.; Benech, H.; Theodoro, F.; Puig, J.; Grau, E.; Garcia, E.; Molto, J.; Grassi, J.; Clotet, B. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunode- ficiency virus-infected patients. Antimicrob. Agents Chemother. 2005, 49, 1907-1914. (Pubitemid 40631606)
12. Vela, J. E.; Olson, L. Y.; Huang, A.; Fridland, A.; Ray, A. S. Simultaneous quantitation of the nucleotide analog adefovir, its phosphorylated anabolites and 2′-deoxyadenosine triphosphate by ion-pairing LC/MS/MS. J. Chromatogr. B 2007, 848, 335-343.
13. Vela, J. E.; Miller, M. D.; Rhodes, G. R.; Ray, A. S. Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools. Antivir. Ther. 2008, 13, 789-797.
14. Chapman, E. H.; Kurec, A. S.; Davey, F. R. Cell volumes of normal and malignant mononuclear cells. J. Clin. Pathol. 1981, 34, 1083-1090.
15. Shaw, J. P.; Sueoko, C. M.; Oliyai, R.; Lee, W. A.; Arimilli, M. N.; Kim, C. U.; Cundy, K. C. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm. Res. 1997, 14, 1824-1829.
16. Diamond, T. L.; Roshal, M.; Jamburuthugoda, V. K.; Reynolds, H. M.; Merriam, A. R.; Lee, K. Y.; Balakrishnan, M.; Bambara, R. A.; Planelles, V.; Dewhurst, S.; Kim, B. Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J. Biol. Chem. 2004, 279, 51545-51553. (Pubitemid 40017904)
17. Hoggard, P. G.; Kewn, S.; Maherbe, A.; Wood, R.; Almond, L. M.; Sales, S. D.; Gould, J.; Lou, Y.; De Vries, C.; Back, D. J.; Khoo, S. H. Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea. AIDS 2002, 16, 2439-2446.
18. Lee, W. A.; Martin, J. C. Perspectives on the development of acyclic nucleotide analogs as antiviral drugs. Antiviral Res. 2006, 71, 254-259.
19. rd; Guyer, B.; Clark, N.; Kearney, B. P. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. JAIDS, J. Acquired Immune Defic. Syndr. 2005, 39, 406-411.
20. Deeks, S. G.; Barditch-Crovo, P.; Lietman, P. S.; Hwang, F.; Cundy, K. C.; Rooney, J. F.; Hellmann, N. S.; Safrin, S.; Kahn, J. O. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIVinfected adults. Antimicrob. Agents Chemother. 1998, 42, 2380-2384.
21. Delaney, W. E. t.; Ray, A. S.; Yang, H.; Qi, X.; Xiong, S.; Zhu, Y.; Miller, M. D. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob. Agents Chemother. 2006, 50, 2471-2477.
22. Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res. 1993, 10, 1093-1095. (Pubitemid 23211439)
23. Ray, A. S.; Cihlar, T.; Robinson, K. L.; Tong, L.; Vela, J. E.; Fuller, M. D.; Wieman, L. M.; Eisenberg, E. J.; Rhodes, G. R. Mechanism of active renal tubular efflux of tenofovir. Antimicrob. Agents Chemother. 2006, 50, 3297-3304.
24. Cihlar, T.; Ray, A. S.; Boojamra, C. G.; Zhang, L.; Hui, H.; Laflamme, G.; Vela, J. E.; Grant, D.; Chen, J.; Myrick, F.; White, K. L.; Gao, Y.; Lin, K. Y.; Douglas, J. L.; Parkin, N. T.; Carey, A.; Pakdaman, R.; Mackman, R. L. Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131. Antimicrob. Agents Chemother. 2008, 52, 655-665.
25. Ray, A. S.; Vela, J. E.; Boojamra, C. G.; Zhang, L.; Hui, H.; Callebaut, C.; Stray, K.; Lin, K. Y.; Gao, Y.; Mackman, R. L.; Cihlar, T. Intracellular metabolism of the nucleotide prodrug GS- 9131, a potent anti-human immunodeficiency virus agent. Antimicrob. Agents Chemother. 2008, 52, 648-654. (Pubitemid 351170841)
26. Reiser, H.; Wang, J.; Chong, L.; Watkins, W. J.; Ray, A. S.; Shibata, R.; Birkus, G.; Cihlar, T.; Wu, S.; Li, B.; Liu, X.; Henne, I. N.; Wolfgang, G. H.; Desai, M.; Rhodes, G. R.; Fridland, A.; Lee, W. A.; Plunkett, W.; Vail, D.; Thamm, D. H.; Jeraj, R.; Tumas, D. B. GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clin. Cancer Res. 2008, 14, 2824-2832.
27. Peyrottes, S.; Egron, D.; Lefebvre, I.; Gosselin, G.; Imbach, J. L.; Perigaud, C. SATE pronucleotide approaches: An overview. Mini-Rev. Med. Chem. 2004, 4, 395-408.
28. Cahard, D.; McGuigan, C.; Balzarini, J. Aryloxy phosphoramidate triesters as pro-tides. Mini-Rev. Med. Chem. 2004, 4, 371-381.
29. Li, F.; Maag, H.; Alfredson, T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J. Pharm. Sci. 2008, 97, 1109-1134.